The method of claim 1 , wherein the patient is a male patient, the sexual dysfunction is erectile dysfunction, the quantity of PDE-5 inhibitor administered and the quantity of PT-141 administered together is sufficient to initiate the desired pharmacological response in the patent and less than the quantity of either PDE-5 inhibitor administered as a monotherapy or PT-141 administered as a monotherapy to treat sexual dysfunction, and the quality of erection score is superior to that obtained from administration of a therapeutically effective amount of a single agent, administered as monotherapy, sufficient to initiate the desired pharmacological response in the patent
How do Gluta One products help with melasma and PIH
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
Furthermore, it is an offence in the ACT to supply peptides without authorisation
Caucasians have an average incidence of 1 in 700 births and individuals of African descent have the lowest incidence of approximately 1 in 1,200 births
Supports gut lining integrity and digestive health